Shilpa Medicare

678.80
+30.70
(4.74%)
ann
There are new updates from the company1 hour ago
Viewcross
right
Market Cap
6,638.05 Cr
EPS
3.67
PE Ratio
74.85
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
959.50
52 Week Low
417.60
PB Ratio
2.72
Debt to Equity
0.48
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from2 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %

Company News

View All News
Caret
positive
Shilpa Medicare Launches Second NDA Bortezomib Injection in US MarketToday
Shilpa Medicare has announced the launch of its second New Drug Application (NDA) for Bortezomib for Injection 3.5mg/1.4mL in the United States. This product is likely a generic version of a cancer treatment medication, expanding the company's presence in the US pharmaceutical market.
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
1,772.00
#1 4,25,162.16
34.87
#1 49,887.20
12.06
#1 9,648
13.77
50.47
5,776.35
1,53,343.94
72.74
8,184.00
0.89
1,600
#1 64.53
46.20
1,499.50
1,21,101.86
23.51
26,520.70
14.17
4,155
47.38
45.27
3,247.35
1,09,905.08
58.33
10,785.70
11.59
1,656
13.54
55.87
2,427.75
1,00,163.75
48.93
10,615.60
19.57
1,942
-16.38
55.89
1,157.35
96,575.69
#1 17.86
28,905.40
12.36
5,578
1.69
45.11
2,087.55
95,305.20
31.98
20,141.50
#1 19.94
1,936
38.82
47.61
908.60
91,426.42
19.78
19,831.50
13.82
3,831
29.92
44.76
1,181.55
68,624.62
19.09
29,559.20
17.55
3,169
-10.04
52.27
30,169.85
64,108.83
47.09
6,097.20
10.80
1,201
16.01
44.78
Growth Rate
Revenue Growth
8.65 %
Net Income Growth
-203.23 %
Cash Flow Change
-24.78 %
ROE
-201.71 %
ROCE
534.38 %
EBITDA Margin (Avg.)
94.38 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
168
151
177
202
203
168
219
186
231
174
209
191
241
203
192
177
203
163
296
241
229
289
288
200
215
239
306
278
346
269
267
266
266
262
315
289
300
302
349
321
Expenses
129
120
137
158
146
139
161
151
171
133
155
159
189
149
128
153
163
132
223
163
175
158
210
171
182
206
243
228
268
241
253
231
227
214
255
222
222
222
258
239
EBITDA
39
31
40
44
58
30
58
35
60
40
54
31
53
54
64
24
41
31
73
78
54
131
78
29
33
33
62
50
78
28
14
34
39
48
60
67
79
80
91
82
Operating Profit %
23 %
19 %
21 %
21 %
26 %
16 %
23 %
17 %
23 %
20 %
24 %
14 %
20 %
25 %
21 %
12 %
19 %
18 %
23 %
31 %
21 %
29 %
25 %
11 %
12 %
13 %
18 %
16 %
21 %
8 %
4 %
12 %
14 %
18 %
19 %
23 %
24 %
24 %
25 %
25 %
Depreciation
5
5
6
6
6
7
7
8
8
9
8
9
11
10
10
11
11
11
11
11
12
12
13
14
15
18
19
21
22
22
23
24
26
27
28
27
27
27
28
29
Interest
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
2
1
1
1
4
4
5
9
10
12
10
9
10
14
18
18
18
23
26
24
24
26
12
Profit Before Tax
32
25
34
37
50
22
50
27
51
31
46
22
41
43
53
11
29
19
62
65
42
115
61
11
8
5
32
19
46
-4
-22
-8
-4
3
9
14
28
29
37
42
Tax
10
7
12
10
12
8
12
10
14
9
12
5
10
10
11
-1
6
4
11
11
8
29
16
3
1
4
12
10
17
-6
-4
-1
4
2
8
10
3
15
19
10
Net Profit
22
18
22
27
38
14
38
17
37
22
34
16
31
33
42
12
23
15
51
55
34
86
45
8
8
2
20
10
30
2
-19
-7
-8
1
2
5
25
14
18
32
EPS in ₹
5.86
4.70
6.05
3.60
4.27
1.92
4.97
2.03
4.33
2.77
4.21
2.29
3.79
4.28
5.22
1.46
2.93
1.93
6.23
6.75
4.24
10.59
5.57
0.94
0.96
0.19
2.45
1.13
3.40
0.10
-2.15
-0.76
-0.93
0.14
0.19
0.53
2.82
1.46
1.83
3.25

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total Assets
905
931
1,472
1,499
1,610
1,989
2,632
2,876
2,904
3,093
Fixed Assets
316
393
492
534
558
650
1,111
1,342
1,368
1,385
Current Assets
328
354
730
672
545
624
903
887
770
877
Capital Work in Progress
222
92
141
210
429
666
541
506
655
719
Investments
65
94
253
140
2
11
21
34
43
40
Other Assets
302
352
587
615
621
662
959
993
838
950
Total Liabilities
905
931
1,472
1,499
1,610
1,989
2,632
2,876
2,904
3,093
Current Liabilities
189
222
237
266
253
411
604
612
784
693
Non Current Liabilities
154
67
251
154
167
257
561
453
345
600
Total Equity
561
642
984
1,080
1,190
1,322
1,468
1,811
1,774
1,800
Reserve & Surplus
539
632
979
1,077
1,189
1,321
1,471
1,814
1,775
1,800
Share Capital
8
8
8
8
8
8
8
9
9
9

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
9
3
93
-26
-40
10
79
-98
-7
11
Investing Activities
-196
-106
-257
-10
-196
-290
-404
-286
-232
-171
Operating Activities
69
129
38
45
147
124
47
105
180
135
Financing Activities
136
-20
313
-61
10
176
436
83
46
47

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Nov 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Apr 2024
Jun 2024
Sept 2024
Dec 2024
Promoter
53.25 %
53.25 %
53.25 %
50.01 %
50.01 %
50.01 %
50.01 %
50.01 %
50.01 %
50.01 %
50.01 %
50.01 %
50.01 %
50.01 %
44.39 %
44.39 %
44.33 %
44.23 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
8.60 %
8.52 %
0.00 %
0.00 %
9.08 %
9.58 %
9.90 %
DIIs
2.95 %
2.05 %
2.29 %
2.15 %
2.12 %
1.01 %
1.01 %
1.01 %
0.61 %
0.54 %
0.00 %
0.41 %
0.06 %
1.59 %
6.13 %
7.61 %
8.18 %
8.27 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
16.80 %
17.89 %
19.49 %
18.23 %
18.57 %
20.12 %
20.51 %
18.95 %
21.85 %
24.05 %
26.82 %
25.40 %
25.45 %
27.64 %
24.54 %
24.69 %
23.94 %
24.40 %
Others
27.01 %
26.81 %
24.97 %
29.61 %
29.31 %
28.87 %
28.47 %
30.03 %
27.52 %
25.40 %
23.17 %
15.59 %
15.96 %
20.75 %
24.94 %
14.23 %
13.96 %
13.21 %
No of Share Holders
51,277
53,220
46,540
40,592
39,565
39,724
39,097
41,579
46,143
46,869
50,434
44,094
43,630
44,793
44,809
41,072
42,784
49,034

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 0.6 0.7 1 1.1 1.1 1.1 0.00 0.00 0.00
Dividend Yield (%) 0.00 0.13 0.21 0.41 0.33 0.28 0.48 0.00 0.00 0.00

Corporate Action

Announcements

Launch Of 2Nd NDA Bortezomib For Injection 3.5Mg/1.4Ml In US1 hour ago
Closure of Trading Window6 days ago
Execution Of Binding Term Sheet With Mabtree Biologics AGMar 17, 2025
Announcement Under Regulation 30 Of The SEBI (LODR) RegulationsMar 14, 2025
Intimation For Participation In Investor ConferenceMar 12, 2025
Disclosure under Regulation 30A of LODRMar 07, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 14, 2025
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Reg 2015Feb 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 11, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationFeb 10, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationFeb 10, 2025
Integrated Filing (Financial)Feb 10, 2025
Unaudited Financial Results For The Quarter Ended 31St December 2024Feb 10, 2025
Board Meeting Outcome for Board Meeting OutcomeFeb 10, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 04, 2025
Board Meeting Intimation for Board Meeting Intimation To Consider The Un-Audited Standalone And Consolidated Financial Results For The Quarter And Nine Months Ended 31 December 2024Feb 03, 2025
Shilpa Pharma Lifesciences Limited Received CEP From EDQM For API TeriflunomideJan 23, 2025
Rejection Letter From BSE For Reclassification Of Mr. Suraj Kumar Innani & Mrs.. Priya InnaniJan 21, 2025
Rejection Letter From NSE On Reclassification Of Mr. Suraj Kumar Innani & Mrs Priya InnaniJan 15, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 10, 2025
Europe Approval For Tadalafil Orodisperible FilmsJan 10, 2025
Closure of Trading WindowDec 30, 2024
Eurasia (EAEU) GMP Approval Of Shilpa Medicare Ltd. Unit IV Jadcherla Telangana And Unit VII Nacharam Hyderabad Telangana.Dec 27, 2024
USFDA Approval Of NDA IMKELDI (Imatinib Oral Solution) Filled By Our Partner Shorla Oncology Developed By Our JV Oncosol LimitedNov 27, 2024
Indian Regulatory Authority - SEC Approval For Conducting Phase III Clinical Trials For Recombinant Human Albumin (Rha) 20%Nov 26, 2024
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 20, 2024
Shilpa Pharma Lifesciences Limited, Received CEP From EDQM For API, NifedipineNov 19, 2024
Shilpa Pharma Lifesciences Limited, Received CEP From EDQM For API, OctreotideNov 18, 2024
Analysts/Investors Call - Call RecordingNov 14, 2024
Monitoring Agency Report For The Quarter Ended 30 September, 2024Nov 14, 2024
Announcement under Regulation 30 (LODR)-Investor PresentationNov 13, 2024
The Un-Audited Financial Results (Standalone And Consolidated) For The Quarter And Half Year Ended 30September 2024.Nov 13, 2024
Board Meeting Outcome for Outcome Of The Meeting Of Board Of Directors Of The Company Held On 13 November 2024Nov 13, 2024
Shilpa Medicare Announces Acceptance By USFDA Of NDA Filed By Its CDMO Partner Unicycive - For Oxylanthanum Carbonate (OLC)Nov 12, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 08, 2024
Board Meeting Intimation for Consider The Un-Audited Standalone And Consolidated Financial Results For The Quarter Ended 30 September 2024Nov 04, 2024
Conclusion Of USFDA Inspection Of Shilpa Medicare Ltd, Unit VI, Bengaluru, Karnataka.Oct 31, 2024
Shilpa Medicare Limited ('SML')'S CDMO Customer Receives Fast-Track Designation For Its Investigational Drug CandidateOct 16, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Oct 14, 2024
Shilpa Pharma Lifesciences Limited, Received CEP From EDQM For API, DesmopressinOct 03, 2024
Closure of Trading WindowSep 28, 2024
Revised Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011.Sep 27, 2024
Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011.Sep 27, 2024
Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.Sep 27, 2024
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.Sep 27, 2024
Revised Disclosure Under Regulation 31 Of SEBI (Substantial Acquisition Of Shares & Takeovers) Regulations, 2011Sep 26, 2024
Disclosure Under Regulation 31 Of SEBI (Substantial Acquisition Of Shares & Takeovers) Regulations, 2011.Sep 24, 2024
Shareholder Meeting / Postal Ballot-Scrutinizer''s ReportSep 19, 2024
Appointment Of Dr. Sridevi Khambhampaty As CEO Of Shilpa Biologicals Pvt. Ltd, A Wholly Owned Subsidiary Of ShilpaMedicare Limited.Sep 19, 2024
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 17, 2024

Technical Indicators

RSI(14)
Neutral
44.79
ATR(14)
Less Volatile
30.70
STOCH(9,6)
Neutral
41.10
STOCH RSI(14)
Neutral
40.59
MACD(12,26)
Bullish
1.95
ADX(14)
Weak Trend
15.44
UO(9)
Bearish
43.54
ROC(12)
Uptrend And Accelerating
3.11
WillR(14)
Neutral
-73.24